{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:42:26Z","timestamp":1771562546042,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.xphs.2021.09.006","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T10:40:37Z","timestamp":1631270437000},"page":"335-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Characterization of N-Terminal Glutamate Cyclization in Monoclonal Antibody and Bispecific Antibody Using Charge Heterogeneity Assays and Hydrophobic Interaction Chromatography"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-4962","authenticated-orcid":false,"given":"Mingyan","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-5197","authenticated-orcid":false,"given":"Niluka","family":"De Mel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9271-0218","authenticated-orcid":false,"given":"Jihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conner","family":"Parthemore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0847-4211","authenticated-orcid":false,"given":"Yang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-4994","authenticated-orcid":false,"given":"Dengfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Kilby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.xphs.2021.09.006_bib0001","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1016\/j.xphs.2019.05.023","article-title":"Cyclization of N-terminal glutamic acid to pyro-glutamic acid impacts monoclonal antibody charge heterogeneity despite its appearance as a neutral transformation","volume":"108","author":"Liu","year":"2019","journal-title":"Journal of pharmaceutical sciences"},{"issue":"7","key":"10.1016\/j.xphs.2021.09.006_bib0002","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/jps.21180","article-title":"Heterogeneity of monoclonal antibodies","volume":"97","author":"Liu","year":"2008","journal-title":"Journal of pharmaceutical sciences"},{"issue":"7","key":"10.1016\/j.xphs.2021.09.006_bib0003","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1021\/ac051827k","article-title":"Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies","volume":"78","author":"Chelius","year":"2006","journal-title":"Analytical chemistry"},{"issue":"4","key":"10.1016\/j.xphs.2021.09.006_bib0004","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jpba.2006.05.008","article-title":"Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development","volume":"42","author":"Yu","year":"2006","journal-title":"Journal of pharmaceutical and biomedical analysis"},{"issue":"37","key":"10.1016\/j.xphs.2021.09.006_bib0005","doi-asserted-by":"crossref","first-page":"13117","DOI":"10.1073\/pnas.0504184102","article-title":"Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation","volume":"102","author":"Huang","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1-3","key":"10.1016\/j.xphs.2021.09.006_bib0006","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-5793(04)00300-X","article-title":"Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions","volume":"563","author":"Schilling","year":"2004","journal-title":"FEBS letters"},{"issue":"13","key":"10.1016\/j.xphs.2021.09.006_bib0007","doi-asserted-by":"crossref","first-page":"11211","DOI":"10.1074\/jbc.M110.185041","article-title":"N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies","volume":"286","author":"Liu","year":"2011","journal-title":"The Journal of biological chemistry"},{"issue":"12","key":"10.1016\/j.xphs.2021.09.006_bib0008","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1021\/ac501451v","article-title":"An artifact in LC-MS\/MS measurement of glutamine and glutamic acid: in-source cyclization to pyroglutamic acid","volume":"86","author":"Purwaha","year":"2014","journal-title":"Analytical chemistry"},{"issue":"7","key":"10.1016\/j.xphs.2021.09.006_bib0009","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1872-2040(08)60114-0","article-title":"N-terminal cyclization of peptides in large-scale protein identification based on biological mass spectrometry","volume":"37","author":"Lu","year":"2009","journal-title":"Chin J Anal Chem"},{"issue":"13","key":"10.1016\/j.xphs.2021.09.006_bib0010","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1021\/acs.analchem.8b00183","article-title":"Use of in vitro systems to model in vivo degradation of therapeutic monoclonal antibodies","volume":"90","author":"Yang","year":"2018","journal-title":"Analytical chemistry"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.006_bib0011","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11095-012-0860-z","article-title":"Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies","volume":"30","author":"Yin","year":"2013","journal-title":"Pharmaceutical research"},{"issue":"8","key":"10.1016\/j.xphs.2021.09.006_bib0012","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/19420862.2016.1225642","article-title":"Charge heterogeneity: basic antibody charge variants with increased binding to Fc receptors","volume":"8","author":"Hintersteiner","year":"2016","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201700476","article-title":"Microheterogeneity of recombinant antibodies: analytics and functional impact","volume":"13","author":"Beyer","year":"2018","journal-title":"Biotechnology journal"},{"issue":"1","key":"10.1016\/j.xphs.2021.09.006_bib0014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ab.2005.10.003","article-title":"Analysis of recombinant monoclonal antibody isoforms by electrospray ionization mass spectrometry as a strategy for streamlining characterization of recombinant monoclonal antibody charge heterogeneity","volume":"348","author":"Lyubarskaya","year":"2006","journal-title":"Analytical biochemistry"},{"key":"10.1016\/j.xphs.2021.09.006_bib0015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.copbio.2014.06.012","article-title":"Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality","volume":"30","author":"Brorson","year":"2014","journal-title":"Current opinion in biotechnology"},{"issue":"11","key":"10.1016\/j.xphs.2021.09.006_bib0016","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1021\/acs.analchem.5b03946","article-title":"Isolation and characterization of monoclonal antibody charge variants by free flow isoelectric focusing","volume":"88","author":"Hosken","year":"2016","journal-title":"Analytical chemistry"},{"issue":"3","key":"10.1016\/j.xphs.2021.09.006_bib0017","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.analchem.7b04608","article-title":"Capillary isoelectric focusing-mass spectrometry method for the separation and online characterization of intact monoclonal antibody charge variants","volume":"90","author":"Dai","year":"2018","journal-title":"Analytical chemistry"},{"key":"10.1016\/j.xphs.2021.09.006_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejps.2018.01.016","article-title":"A comprehensive approach for evaluating charge heterogeneity in biosimilars","volume":"115","author":"Xiao","year":"2018","journal-title":"European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences"},{"issue":"2","key":"10.1016\/j.xphs.2021.09.006_bib0019","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/19420862.2018.1553476","article-title":"Structure, heterogeneity and developability assessment of therapeutic antibodies","volume":"11","author":"Xu","year":"2019","journal-title":"mAbs"},{"issue":"1-2","key":"10.1016\/j.xphs.2021.09.006_bib0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.chroma.2008.10.078","article-title":"Separation of populations of antibody variants by fine tuning of hydrophobic-interaction chromatography operating conditions","volume":"1214","author":"Valliere-Douglass","year":"2008","journal-title":"Journal of chromatography. A"},{"issue":"13-14","key":"10.1016\/j.xphs.2021.09.006_bib0021","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jchromb.2011.03.006","article-title":"HIC resolution of an IgG1 with an oxidized Trp in a complementarity determining region","volume":"879","author":"Boyd","year":"2011","journal-title":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"},{"issue":"4","key":"10.1016\/j.xphs.2021.09.006_bib0022","doi-asserted-by":"crossref","first-page":"852","DOI":"10.4161\/mabs.28693","article-title":"Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications","volume":"6","author":"Haverick","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2021.09.006_bib0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jpba.2016.04.004","article-title":"Hydrophobic interaction chromatography for the characterization of monoclonal antibodies and related products","volume":"130","author":"Fekete","year":"2016","journal-title":"Journal of pharmaceutical and biomedical analysis"},{"issue":"8","key":"10.1016\/j.xphs.2021.09.006_bib0024","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.xphs.2021.04.010","article-title":"Characterization and Monitoring of a Novel Light-heavy-light Chain Mispair in a Therapeutic Bispecific Antibody","volume":"110","author":"Cao","year":"2021","journal-title":"Journal of pharmaceutical sciences"},{"key":"10.1016\/j.xphs.2021.09.006_bib0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ab.2018.11.021","article-title":"Characterization and quantification of succinimide using peptide mapping under low-pH conditions and hydrophobic interaction chromatography","volume":"566","author":"Cao","year":"2019","journal-title":"Analytical biochemistry"},{"issue":"6","key":"10.1016\/j.xphs.2021.09.006_bib0026","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/19420862.2019.1624127","article-title":"Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis","volume":"11","author":"Cao","year":"2019","journal-title":"mAbs"},{"issue":"8","key":"10.1016\/j.xphs.2021.09.006_bib0027","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/19420862.2018.1511198","article-title":"A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture","volume":"10","author":"Wang","year":"2018","journal-title":"mAbs"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921004767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921004767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:36:07Z","timestamp":1758360967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921004767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0022354921004767"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.09.006","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of N-Terminal Glutamate Cyclization in Monoclonal Antibody and Bispecific Antibody Using Charge Heterogeneity Assays and Hydrophobic Interaction Chromatography","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}